Particle.news
Download on the App Store
34 ARTICLES
·
19h ago

Regeneron to Acquire 23andMe for $256 Million Following Bankruptcy Auction

The deal includes 23andMe’s genomic services and biobank, with privacy protections under court oversight, and is expected to close in Q3 2025.

Image
FILE PHOTO: Attendees visit the 23andMe booth at the RootsTech annual genealogical event in Salt Lake City, Utah, U.S., February 28, 2019. REUTERS/George Frey/File Photo
Image

Overview

  • Regeneron Pharmaceuticals has agreed to purchase 23andMe’s core assets, including its Personal Genome Service, Total Health and Research Services, and biobank, for $256 million.
  • The acquisition excludes 23andMe's Lemonaid Health subsidiary, which will be wound down as part of the bankruptcy process.
  • The sale requires approval by the U.S. Bankruptcy Court for the Eastern District of Missouri, with a hearing scheduled for June 17, 2025, and the transaction expected to close in the third quarter.
  • Regeneron has committed to adhering to 23andMe’s existing privacy policies and applicable laws, with a court-appointed consumer privacy ombudsman set to review the transaction.
  • 23andMe filed for Chapter 11 bankruptcy in March 2025 after financial struggles, a 2023 data breach affecting 7 million users, and the resignation of CEO Anne Wojcicki.